These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 30521987)

  • 21. Profiling of the genetic features of patients with breast, ovarian, colorectal and extracolonic cancers: Association to CHEK2 and PALB2 germline mutations.
    Infante M; Arranz-Ledo M; Lastra E; Olaverri A; Ferreira R; Orozco M; Hernández L; Martínez N; Durán M
    Clin Chim Acta; 2024 Jan; 552():117695. PubMed ID: 38061684
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interdisciplinary risk counseling for hereditary breast and ovarian cancer: real-world data from a specialized center.
    Zang B; Helms M; Besch L; Kalmbach N; Stegen S; Blohmer JU; Speiser D
    Arch Gynecol Obstet; 2023 May; 307(5):1585-1592. PubMed ID: 36307613
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Current clinical issues and recent trends in hereditary breast and ovarian cancer in Japan-genetic testing for HBOC and risk-reducing surgery].
    Arai M; Iwase T; Takazawa Y; Takeshima N
    Gan To Kagaku Ryoho; 2014 Nov; 41(11):1333-9. PubMed ID: 25434434
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Screening of over 1000 Indian patients with breast and/or ovarian cancer with a multi-gene panel: prevalence of BRCA1/2 and non-BRCA mutations.
    Singh J; Thota N; Singh S; Padhi S; Mohan P; Deshwal S; Sur S; Ghosh M; Agarwal A; Sarin R; Ahmed R; Almel S; Chakraborti B; Raina V; DadiReddy PK; Smruti BK; Rajappa S; Dodagoudar C; Aggarwal S; Singhal M; Joshi A; Kumar R; Kumar A; Mishra DK; Arora N; Karaba A; Sankaran S; Katragadda S; Ghosh A; Veeramachaneni V; Hariharan R; Mannan AU
    Breast Cancer Res Treat; 2018 Jul; 170(1):189-196. PubMed ID: 29470806
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alternative transcript imbalance underlying breast cancer susceptibility in a family carrying PALB2 c.3201+5G>T.
    Duran-Lozano L; Montalban G; Bonache S; Moles-Fernández A; Tenés A; Castroviejo-Bermejo M; Carrasco E; López-Fernández A; Torres-Esquius S; Gadea N; Stjepanovic N; Balmaña J; Gutiérrez-Enríquez S; Diez O
    Breast Cancer Res Treat; 2019 Apr; 174(2):543-550. PubMed ID: 30552643
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Functional characterization of 84 PALB2 variants of uncertain significance.
    Wiltshire T; Ducy M; Foo TK; Hu C; Lee KY; Belur Nagaraj A; Rodrigue A; Gomes TT; Simard J; Monteiro ANA; Xia B; Carvalho MA; Masson JY; Couch FJ
    Genet Med; 2020 Mar; 22(3):622-632. PubMed ID: 31636395
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PALB2 germline mutations in a multi-gene panel testing cohort of 1905 breast-ovarian cancer patients in Argentina.
    Gonzalez A; Del Greco F; Vargas-Roig L; Brun B; Tabares G; Mampel A; Montes C; Martin C; Lopez M; Rossi N; Bruno L; Ponce C; Quaglio P; Yanzi A; Acevedo S; Lugo L; Lopez Breccia P; Avila S; Sisterna S; Del Castillo MS; Vazquez M; Nuñez LM
    Breast Cancer Res Treat; 2022 Jul; 194(2):403-412. PubMed ID: 35610400
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Spectrum and characteristics of germline PALB2 pathogenic variants in 1556 early-onset breast cancer patients in China.
    Li J; He P; Cai Q; Chen L; Wang Y; Cai W; Qiu Y; Liu S; Guo W; Chen M; Lin Y; Wang C; Fu F
    J Cancer Res Clin Oncol; 2024 Jun; 150(6):322. PubMed ID: 38914840
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of PALB2 in a cohort of Italian breast cancer patients: identification of a novel PALB2 truncating mutation.
    Vietri MT; Caliendo G; Schiano C; Casamassimi A; Molinari AM; Napoli C; Cioffi M
    Fam Cancer; 2015 Sep; 14(3):341-8. PubMed ID: 25666743
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mutation analysis of PALB2 gene in French breast cancer families.
    Damiola F; Schultz I; Barjhoux L; Sornin V; Dondon MG; Eon-Marchais S; Marcou M; ; Caron O; Gauthier-Villars M; de Pauw A; Luporsi E; Berthet P; Delnatte C; Bonadona V; Maugard C; Pujol P; Lasset C; Longy M; Bignon YJ; Fricker JP; Andrieu N; Sinilnikova OM; Stoppa-Lyonnet D; Mazoyer S; Muller D
    Breast Cancer Res Treat; 2015 Dec; 154(3):463-71. PubMed ID: 26564480
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of a novel truncating PALB2 mutation and analysis of its contribution to early-onset breast cancer in French-Canadian women.
    Foulkes WD; Ghadirian P; Akbari MR; Hamel N; Giroux S; Sabbaghian N; Darnel A; Royer R; Poll A; Fafard E; Robidoux A; Martin G; Bismar TA; Tischkowitz M; Rousseau F; Narod SA
    Breast Cancer Res; 2007; 9(6):R83. PubMed ID: 18053174
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The French Genetic and Cancer Consortium guidelines for multigene panel analysis in hereditary breast and ovarian cancer predisposition].
    Moretta J; Berthet P; Bonadona V; Caron O; Cohen-Haguenauer O; Colas C; Corsini C; Cusin V; De Pauw A; Delnatte C; Dussart S; Jamain C; Longy M; Luporsi E; Maugard C; Nguyen TD; Pujol P; Vaur D; Andrieu N; Lasset C; Noguès C;
    Bull Cancer; 2018 Oct; 105(10):907-917. PubMed ID: 30268633
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Analysis of PALB2 mutations in 155 Japanese patients with breast and/or ovarian cancer.
    Nakagomi H; Sakamoto I; Hirotsu Y; Amemiya K; Mochiduki H; Omata M
    Int J Clin Oncol; 2016 Apr; 21(2):270-275. PubMed ID: 26411315
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CHEK2 1100delC and Del5395bp mutations in BRCA-negative individuals from Serbian hereditary breast and ovarian cancer families.
    Krivokuca A; Dobricic J; Brankovic-Magic M
    J BUON; 2013; 18(3):594-600. PubMed ID: 24065469
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Heterozygous mutations in the PALB2 hereditary breast cancer predisposition gene impact on the three-dimensional nuclear organization of patient-derived cell lines.
    Wark L; Novak D; Sabbaghian N; Amrein L; Jangamreddy JR; Cheang M; Pouchet C; Aloyz R; Foulkes WD; Mai S; Tischkowitz M
    Genes Chromosomes Cancer; 2013 May; 52(5):480-94. PubMed ID: 23341105
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PALB2 analysis in BRCA2-like families.
    Adank MA; van Mil SE; Gille JJ; Waisfisz Q; Meijers-Heijboer H
    Breast Cancer Res Treat; 2011 Jun; 127(2):357-62. PubMed ID: 20582465
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [PALB2, a major susceptibility gene for breast cancer].
    Piffer A; Luporsi E; Mathelin C
    Gynecol Obstet Fertil Senol; 2018 Nov; 46(10-11):701-705. PubMed ID: 30243941
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A synonymous germline variant PALB2 c.18G>T (p.Gly6=) disrupts normal splicing in a family with pancreatic and breast cancers.
    Yang C; Ceyhan-Birsoy O; Mandelker D; Jairam S; Catchings A; O'Reilly EM; Walsh MF; Zhang L
    Breast Cancer Res Treat; 2019 Jan; 173(1):79-86. PubMed ID: 30255452
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of a novel PTT assay for mutation detection in PALB2 large exons and PALB2 screening in medullary breast cancer.
    Poumpouridou N; Goutas N; Tsionou C; Dimas K; Lianidou E; Kroupis C
    Fam Cancer; 2016 Apr; 15(2):183-91. PubMed ID: 26573693
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Frequency of germline PALB2 mutations among women with epithelial ovarian cancer.
    Kotsopoulos J; Sopik V; Rosen B; Fan I; McLaughlin JR; Risch H; Sun P; Narod SA; Akbari MR
    Fam Cancer; 2017 Jan; 16(1):29-34. PubMed ID: 27631815
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.